No Record Found
Sector
PharmaceuticalsOpen
₹119.3Prev. Close
₹116.96Turnover(Lac.)
₹59.42Day's High
₹119.3Day's Low
₹115.352 Week's High
₹31752 Week's Low
₹98Book Value
₹28.96Face Value
₹1Mkt Cap (₹ Cr.)
1,066.1P/E
0EPS
0Divi. Yield
0.43No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 9.2 | 9.2 | 9.2 | 9.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 311.08 | 292.07 | 272.62 | 234.28 |
Net Worth | 320.28 | 301.27 | 281.82 | 243.48 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 230.66 | 201.58 | 209.5 | 216.65 |
yoy growth (%) | 14.42 | -3.77 | -3.3 | 6.78 |
Raw materials | -78.2 | -63.18 | -71.66 | -70.7 |
As % of sales | 33.9 | 31.34 | 34.2 | 32.63 |
Employee costs | -39.98 | -44.27 | -44.61 | -39.99 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 32.24 | 18 | 9.39 | 16.39 |
Depreciation | -8.54 | -8.26 | -7.4 | -7.47 |
Tax paid | -5.62 | -2.09 | -0.1 | -1.6 |
Working capital | 7.89 | 27.14 | 18.07 | 18.93 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.42 | -3.77 | -3.3 | 6.78 |
Op profit growth | 39.8 | 39.17 | -21.85 | 4.4 |
EBIT growth | 45.57 | 45.24 | -24.69 | 5.8 |
Net profit growth | 67.29 | 71.19 | -37.16 | -1.8 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 405.51 | 381.76 | 354.32 | 394.61 | 230.67 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 405.51 | 381.76 | 354.32 | 394.61 | 230.67 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 10.59 | 23.56 | 25.12 | 17.88 | 13.1 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,763.9 | 90.54 | 4,23,170.71 | 564.22 | 0.91 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,518.5 | 68.88 | 1,73,171.79 | 696 | 0.46 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,819.4 | 60.53 | 1,29,170.36 | 597 | 0.16 | 2,707 | 249.83 |
Cipla Ltd CIPLA | 1,535.6 | 23.87 | 1,24,093.85 | 1,210.53 | 1.04 | 4,495.16 | 411.56 |
Dr Reddys Laboratories Ltd DRREDDY | 1,244.4 | 19.24 | 1,03,868.61 | 387.3 | 0.64 | 4,602.9 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Exec. Director
Dinesh S Patel
ED / MD / CEO / Promoter
Sachin D Patel
Non-Exec & Non-Independent Dir
Reena S Patel
Non-Exec & Non-Independent Dir
Rajneesh Anand
Non-Exec & Non-Independent Dir
Adam Demeter
Independent Non Exe. Director
Bhaskar Vemban Iyer
Independent Non Exe. Director
Shishir Dalal
Independent Non Exe. Director
Nikunt Raval
Independent Director
Neha Thakore
Plot No 69 A GIDC Indl Estate,
Vapi,
Gujarat - 396195
Tel: 91-260-2421675
Website: http://www.themismedicare.com
Email: sangameshwar.iyer@themismedicare.com; cfoassist@th
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Themis Medicare Limited was formerly incorporated as Themis Chemicals Limited in 1969. The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibh...
Read More
Reports by Themis Medicare Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.